---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-000666"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:24:06.350488+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Replimune appoints Chris Sarchi as CCO and Sushil Patel as Chief Strategy Officer, effective immediately

## Summary
- Chris Sarchi, former Sanofi U.S. Commercial Oncology Head, named Chief Commercial Officer.
- Sushil Patel, previously CCO, transitions to newly created Chief Strategy Officer role.
- Appointments aim to ramp up commercial planning ahead of potential 2024 launch of RP1.
- Sarchi led Libtayo launch in CSCC; Patel will lead ex-U.S. strategy and platform planning.

## SEC filing metadata
- accession: 0001104659-23-000666
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465923000666/0001104659-23-000666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465923000666/tm231486d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-000666
- JSON: https://secwatch.observer/filing/0001104659-23-000666.json
- Plain text: https://secwatch.observer/filing/0001104659-23-000666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.